Indaptus Therapeutics Stock Analysis

INDP Stock  USD 2.30  0.01  0.43%   
Indaptus Therapeutics is undervalued with Real Value of 3.64 and Target Price of 8.0. The main objective of Indaptus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Indaptus Therapeutics is worth, separate from its market price. There are two main types of Indaptus Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Indaptus Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Indaptus Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Indaptus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Indaptus Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Indaptus Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Indaptus Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

Indaptus Stock Analysis Notes

About 31.0% of the company shares are held by company insiders. The book value of Indaptus Therapeutics was currently reported as 1.44. The company recorded a loss per share of 1.83. Indaptus Therapeutics last dividend was issued on the 30th of October 2020. The entity had 1:4 split on the 27th of July 2021. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Indaptus Therapeutics call Jeffrey Meckler at 646 427 2727 or check out https://indaptusrx.com.

Indaptus Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Indaptus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Indaptus Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Indaptus Therapeutics is way too risky over 90 days horizon
Indaptus Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (15.42 M) with profit before overhead, payroll, taxes, and interest of 0.
Indaptus Therapeutics currently holds about 33.01 M in cash with (13.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from news.google.com: Heres Why Were Watching Indaptus Therapeutics Cash Burn Situation - Yahoo Lifestyle Australia

Indaptus Therapeutics Upcoming and Recent Events

Earnings reports are used by Indaptus Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Indaptus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
15th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Indaptus Largest EPS Surprises

Earnings surprises can significantly impact Indaptus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-20
2023-12-31-0.54-0.480.0611 
2023-11-06
2023-09-30-0.55-0.470.0814 
2023-05-11
2023-03-31-0.59-0.510.0813 
View All Earnings Estimates

Indaptus Therapeutics Environmental, Social, and Governance (ESG) Scores

Indaptus Therapeutics' ESG score is a quantitative measure that evaluates Indaptus Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Indaptus Therapeutics' operations that may have significant financial implications and affect Indaptus Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Indaptus Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Indaptus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Indaptus Therapeutics backward and forwards among themselves. Indaptus Therapeutics' institutional investor refers to the entity that pools money to purchase Indaptus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bangor Savings Bank2024-03-31
400
Wells Fargo & Co2023-12-31
104
Royal Bank Of Canada2023-12-31
38.0
Jpmorgan Chase & Co2023-12-31
9.0
Group One Trading, Lp2023-12-31
7.0
Bank Of America Corp2023-12-31
3.0
Qube Research & Technologies2023-12-31
1.0
Northern Trust Corp2023-09-30
0.0
Vanguard Group Inc2023-12-31
256.3 K
Investment House Llc2023-12-31
102.4 K
Geode Capital Management, Llc2023-12-31
54.8 K
Note, although Indaptus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Indaptus Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Indaptus Therapeutics's market, we take the total number of its shares issued and multiply it by Indaptus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Indaptus Profitablity

Indaptus Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Indaptus Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Indaptus Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Indaptus Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Indaptus Therapeutics' profitability requires more research than a typical breakdown of Indaptus Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.03)(1.09)
Return On Capital Employed(1.35)(1.28)
Return On Assets(1.03)(1.09)
Return On Equity(1.28)(1.21)

Management Efficiency

Indaptus Therapeutics has return on total asset (ROA) of (0.4763) % which means that it has lost $0.4763 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8404) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/21/2024, Return On Tangible Assets is likely to drop to -1.09. In addition to that, Return On Capital Employed is likely to grow to -1.28. At this time, Indaptus Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 05/21/2024, Liabilities And Stockholders Equity is likely to grow to about 23.5 M, while Non Current Liabilities Total is likely to drop slightly above 69.7 K.
Last ReportedProjected for Next Year
Book Value Per Share 1.44  1.37 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 1.44  1.37 
Enterprise Value Over EBITDA(0.1)(0.09)
Price Book Value Ratio 1.22  1.29 
Enterprise Value Multiple(0.1)(0.09)
Price Fair Value 1.22  1.29 
Enterprise Value1.6 M1.7 M
The analysis of Indaptus Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Indaptus Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Indaptus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.194

Technical Drivers

As of the 21st of May, Indaptus Therapeutics retains the Downside Deviation of 5.85, risk adjusted performance of 0.0722, and Market Risk Adjusted Performance of (10.78). Indaptus Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Indaptus Therapeutics, which can be compared to its competitors. Please check out Indaptus Therapeutics variance, as well as the relationship between the value at risk and skewness to decide if Indaptus Therapeutics is priced fairly, providing market reflects its last-minute price of 2.3 per share. Please also validate Indaptus Therapeutics total risk alpha, which is currently at (0.06) to confirm the company can sustain itself at a future point.

Indaptus Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Indaptus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Indaptus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Indaptus Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Indaptus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Indaptus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Indaptus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Indaptus Therapeutics Predictive Daily Indicators

Indaptus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Indaptus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Indaptus Therapeutics Corporate Filings

8K
8th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
26th of April 2024
Other Reports
ViewVerify
8K
25th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
13th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
4th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
23rd of January 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
6th of November 2023
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
31st of October 2023
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Indaptus Therapeutics Forecast Models

Indaptus Therapeutics' time-series forecasting models are one of many Indaptus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Indaptus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Indaptus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Indaptus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Indaptus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Indaptus Therapeutics. By using and applying Indaptus Stock analysis, traders can create a robust methodology for identifying Indaptus entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.00  0.00 
Operating Profit Margin 0.00  0.00 
Net Profit Margin 0.00  0.00 
Gross Profit Margin 0.00  0.00 

Current Indaptus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Indaptus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Indaptus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
8.0Buy2Odds
Indaptus Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Indaptus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Indaptus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Indaptus Therapeutics, talking to its executives and customers, or listening to Indaptus conference calls.
Indaptus Analyst Advice Details

Indaptus Stock Analysis Indicators

Indaptus Therapeutics stock analysis indicators help investors evaluate how Indaptus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Indaptus Therapeutics shares will generate the highest return on investment. By understating and applying Indaptus Therapeutics stock analysis, traders can identify Indaptus Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow9.6 M
Common Stock Shares Outstanding8.4 M
Total Stockholder Equity12.1 M
Property Plant And Equipment Net173.9 K
Cash And Short Term Investments13.4 M
Cash13.4 M
Accounts Payable806 K
Net Debt-13.2 M
50 Day M A2.2802
Total Current Liabilities2.8 M
Other Operating Expenses16.4 M
Non Current Assets Total928.7 K
Non Currrent Assets Other754.7 K
Stock Based CompensationM
When determining whether Indaptus Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Indaptus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Indaptus Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Indaptus Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.
Note that the Indaptus Therapeutics information on this page should be used as a complementary analysis to other Indaptus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Indaptus Stock analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is Indaptus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Indaptus Therapeutics. If investors know Indaptus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Indaptus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.83)
Return On Assets
(0.48)
Return On Equity
(0.84)
The market value of Indaptus Therapeutics is measured differently than its book value, which is the value of Indaptus that is recorded on the company's balance sheet. Investors also form their own opinion of Indaptus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Indaptus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Indaptus Therapeutics' market value can be influenced by many factors that don't directly affect Indaptus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Indaptus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Indaptus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Indaptus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.